Search Results - "Lindhoff‐Last, Edelgard"

Fondaparinux Pre-, Peri-, and/or Postpartum for the Prophylaxis/Treatment of Venous Thromboembolism (FondaPPP) by Dempfle, Carl-Erik, Koscielny, Jürgen, Lindhoff-Last, Edelgard, Linnemann, Birgit, Bux-Gewehr, Irene, Kappert, Günther, Scholz, Ute, Kropff, Stefan, Eberle, Sonja, Bramlage, Peter, Heinken, Andreas

“…We analyzed data for women who received fondaparinux for ≥7 days during pregnancy. The study retrospectively included women who received fondaparinux pre-,…”
Get full text

Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry by Pfeilschifter, Waltraud, Lindhoff-Last, Edelgard, Alhashim, Ali, Zydek, Barbara, Lindau, Simone, Konstantinides, Stavros, Grottke, Oliver, Nowak-Göttl, Ulrike, von Heymann, Christian, Birschmann, Ingvild, Beyer-Westendorf, Jan, Meybohm, Patrick, Greinacher, Andreas, Herrmann, Eva

“…The use of direct oral anticoagulants (DOAC) has increased sharply and DOAC are the oral anticoagulant therapy (OAT) of choice for the majority of patients…”
Get full text

The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination by Ott, Olivia, Herrmann, Eva, Schulz, Annabel, Lindhoff-Last, Edelgard

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and…”
Get full text

Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions by Mani, Helen, Hesse, Christian, Stratmann, Gertrud, Lindhoff-Last, Edelgard

“…Global coagulation assays display variable effects at different concentrations of rivaroxaban. The aim of this study is to quantify the ex vivo effects of…”
Get more information

Clinical and cardiac magnetic resonance findings in post-COVID patients referred for suspected myocarditis by Breitbart, Philipp, Koch, Alexander, Schmidt, Marco, Magedanz, Annett, Lindhoff-Last, Edelgard, Voigtländer, Thomas, Schmermund, Axel, Mehta, Rajendra H., Eggebrecht, Holger

“…Objectives We assessed possible myocardial involvement in previously cardiac healthy post-COVID patients referred for persisting symptoms with suspected…”
Get full text

Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry by Weingarz, Lea, Schwonberg, Jan, Schindewolf, Marc, Hecking, Carola, Wolf, Zsuzsanna, Erbe, Matthias, Weber, Adele, Lindhoff‐Last, Edelgard, Linnemann, Birgit

“…Summary Thrombophilia is a well‐established risk factor for a venous thromboembolic event (VTE), and it has been proposed that hereditary thrombophilia may…”
Get full text

Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke by Pfeilschifter, Waltraud, Bohmann, Ferdinand, Baumgarten, Peter, Mittelbronn, Michel, Pfeilschifter, Josef, Lindhoff-Last, Edelgard, Steinmetz, Helmuth, Foerch, Christian

“…Objective: Anticoagulation with dabigatran etexilate (DE) has a favorable risk‐to‐benefit profile for the prevention of ischemic events in patients with atrial…”
Get full text

Heparin-induced skin lesions by Schindewolf, Marc, MD, Lindhoff-Last, Edelgard, Prof, Ludwig, Ralf J, Prof, Boehncke, Wolf-Henning, Prof

“…Summary Heparins are widely used for prophylaxis and treatment of thromboembolic diseases. Besides bleeding complications, heparin-induced skin lesions are the…”
Get full text

Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time by Mani, Helen, Hesse, Christian, Stratmann, Gertrud, Lindhoff-Last, Edelgard

“…It was the objective of this study to quantify the effects of rivaroxaban administration on global coagulation parameters associated with routine clinical…”
Get more information

Measuring the anticoagulant effects of target specific oral anticoagulants—reasons, methods and current limitations by Mani, Helen, Kasper, Alexander, Lindhoff-Last, Edelgard

“…To simplify and optimize oral anticoagulation, new target-specific oral anticoagulants (TSOAs) have been developed. The direct thrombin-inhibitor dabigatran…”
Get full text

Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs by Thaler, Markus A, Bietenbeck, Andreas, Steigerwald, Udo, Büttner, Thomas, Schierack, Peter, Lindhoff-Last, Edelgard, Roggenbuck, Dirk, Luppa, Peter B

“…Persistent antiphospholipid antibodies (aPL) constitute the serological hallmark of the antiphospholipid syndrome (APS). Recently, various new assay…”
Get full text

Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency by Luxembourg, Beate, Pavlova, Anna, Geisen, Christof, Spannagl, Michael, Bergmann, Frauke, Krause, Manuela, Alesci, Sonja, Seifried, Erhard, Lindhoff-Last, Edelgard

“…Mutations in the antithrombin (AT) gene can impair the capacity of AT to bind heparin (AT deficiency type IIHBS), its target proteases such as thrombin (type…”
Get more information

Nadroparin carries a potentially high risk of inducing cutaneous delayed‐type hypersensitivity responses by Schindewolf, Marc, Recke, Andreas, Zillikens, Detlef, Lindhoff‐Last, Edelgard, Ludwig, Ralf J.

“…Summary Background Heparins are widely used for the prophylaxis/treatment of thromboembolic events. As adverse effects, heparin‐induced skin lesions occur…”
Get full text

The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation by Pfeilschifter, Waltraud, Luger, Sebastian, Brunkhorst, Robert, Lindhoff-Last, Edelgard, Foerch, Christian

“…The novel direct oral anticoagulants (NOA), dabigatran (a thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors) have shown at least…”
Get more information

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke by Bohmann, Ferdinand, Mirceska, Ana, Pfeilschifter, Josef, Lindhoff-Last, Edelgard, Steinmetz, Helmuth, Foerch, Christian, Pfeilschifter, Waltraud

“…Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to…”
Get full text

Molecular basis of antithrombin deficiency by Luxembourg, Beate, Delev, Daniel, Geisen, Christof, Spannagl, Michael, Krause, Manuela, Miesbach, Wolfgang, Heller, Christine, Bergmann, Frauke, Schmeink, Ursula, Grossmann, Ralf, Lindhoff-Last, Edelgard, Seifried, Erhard, Oldenburg, Johannes, Pavlova, Anna

“…Antithrombin (AT) is the most important physiological inhibitor of coagulation proteases. It is activated by glycosaminoglycans such as heparin. Hereditary…”
Get more information

Pharmacokinetics of Phenprocoumon in Emergency Situations-Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry) by Lindhoff-Last, Edelgard, Birschmann, Ingvild, Bidenharn, Antonia J, Kuhn, Joachim, Lindau, Simone, Konstantinides, Stavros, Grottke, Oliver, Nowak-Göttl, Ulrike, Lucks, Jessica, Zydek, Barbara, von Heymann, Christian, Sümnig, Ariane, Beyer-Westendorf, Jan, Schellong, Sebastian, Meybohm, Patrick, Greinacher, Andreas, Herrmann, Eva

“…Background: Phenprocoumon has been used as an oral anticoagulant in patients with thromboembolic disease for more than 40 years. So far its pharmacokinetics…”
Get full text

High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy by Schindewolf, Marc, MD, Gobst, Corinna, MD, Kroll, Hartmut, MD, Recke, Andreas, MD, Louwen, Frank, MD, Wolter, Manfred, MD, Kaufmann, Roland, MD, Boehncke, Wolf-Henning, MD, Lindhoff-Last, Edelgard, MD, Ludwig, Ralf J., MD

“…Background Among the most frequent adverse effects of subcutaneous heparin treatment, heparin-induced skin lesions occur with an incidence of 10.3% in…”
Get full text

Hereditary and acquired thrombophilia in patients with upper extremity deep-vein thrombosis. Results from the MAISTHRO registry by Linnemann, Birgit, Meister, Florian, Schwonberg, Jan, Schindewolf, Marc, Zgouras, Dimitrios, Lindhoff-Last, Edelgard

“…The prevalence of coagulation disorders in patients with upper extremity deep-vein thrombosis (UE-DVT) is unknown due to only a few observational studies of…”
Get more information

Thrombosis of the inferior vena cava and malignant disease by Kraft, Christiane, Schuettfort, Gundolf, Weil, Yvonne, Tirneci, Vanessa, Kasper, Alexander, Haberichter, Barbara, Schwonberg, Jan, Schindewolf, Marc, Lindhoff-Last, Edelgard, Linnemann, Birgit

“…Abstract Background Inferior vena cava thrombosis (IVCT) is a rare event, and studies detailing its underlying aetiologies are scarce. Methods One hundred and…”
Get full text